ホーム>>Signaling Pathways>> PROTAC>> E3 Ligase Ligand-Linker Conjugate>>E3 ligase Ligand-Linker Conjugates 12

E3 ligase Ligand-Linker Conjugates 12 (Synonyms: VH032-PEG3-N3; VHL Ligand-Linker Conjugates 8; E3 ligase Ligand-Linker Conjugates 12)

カタログ番号GC33000

E3 リガーゼ リガンド-リンカー コンジュゲート 12 は、PROTAC テクノロジーで使用される (S,R,S)-AHPC ベースの VHL リガンドと 3 ユニット PEG リンカーを組み込んだ合成 E3 リガーゼ リガンド-リンカー コンジュゲートです。

Products are for research use only. Not for human use. We do not sell to patients.

E3 ligase Ligand-Linker Conjugates 12 化学構造

Cas No.: 1797406-80-4

サイズ 価格 在庫数 個数
100mg
$279.00
在庫あり
500mg
$1,080.00
在庫あり
1g
$1,993.00
在庫あり
2g
$2,790.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

E3 ligase Ligand-Linker Conjugates 12 is a synthesized compound that incorporates an E3 ligase ligand and a linker used in PROTAC technology.

E3 ligase Ligand-Linker Conjugates 12 is extracted from patent WO/2016/146985A1, figure 11. PROTAC has been developed having structure A-L-B that can tether a bromodomain inhibitor via a moiety which binds to a protein within the bromo- and Extra-terminal (BET) family of proteins to a small molecule E3 ubiquintin ligase protein binding ligand compond via a suitable linker[1][2].

[1]. WO/2016/146985A1 [2]. Zengerle M, et al. Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4. ACS Chem Biol. 2015 Aug 21;10(8):1770-7.

レビュー

Review for E3 ligase Ligand-Linker Conjugates 12

Average Rating: 5 ★★★★★ (Based on Reviews and 12 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for E3 ligase Ligand-Linker Conjugates 12

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.